

The background features a dark blue gradient with faint, light blue concentric circles and degree markings (40, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260) on the left side, suggesting a circular or orbital theme.

NEJM AI NEJM EVIDENCE NEJM新英格兰杂志

校外CARSI（机构）登录教程

中山大学图书馆
张老师 2026/10/22 整理
zhanghj36@mail.sysu.edu.cn

数据库名称	NEJM Evidence新英格兰杂志-循证医学子刊
访问入口	<div>1https://evidence.nejm.org/</div>
学科范围	医药卫生, 常用医学资源
文献类型	期刊
语言	英文
别名	New England Journal of Medicine-Evidence

数据库名称	NEJM AI 英格兰医学杂志人工智能特刊
访问入口	<div>官网入口 (直达) OVID平台入口 (需搜</div>
学科范围	<div>1医药卫生, 常用医学资源, 电子通信/计算</div>
文献类型	期刊
语言	英文
别名	

数据库名称	The New Engl
访问入口	<div>1http://www.ne</div>
学科范围	医药卫生, 常用
文献类型	期刊
语言	英文
别名	NEJM

选择官网入口



SIGN IN

CREATE ACCOUNT

SUBSCRIBE



The NEW ENGLAND
JOURNAL of MEDICINE

CURRENT ISSUE ▾

SPECIALTIES ▾

TOPICS ▾

MULTIMEDIA ▾

LEARNING/CME ▾

AUTHOR CENTER



② 点击数据库页面

右上方 SIGN IN

ORIGINAL ARTICLE CME

Milvexian after an Acute Coronary Syndrome Event

C.M. Gibson and Others


Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding.

Editorial Role for Factor XIa Inhibitors after an Acute Coronary Syndrome Event

Quick Take Video RS Research Summary



IMAGE CHALLENGE →




What is the diagnosis?

ANSWER →

ORIGINAL ARTICLE

Ianalumab for Active Sjögren's Disease

X. Mariette and Others



PUBLIC HEALTH ALERTS

Reports from the Frontlines

Receive immediate
email notification when
new reports are published



The NEW ENGLAND
JOURNAL of MEDICINE

CURRENT ISSUE ▾ SPECIALTIES ▾ TOPICS ▾ MULTIMEDIA ▾ LEARNING/CME ▾ AUTHOR CENTER 🔍

③ 选择 机构登录

Sign In

选择 SHIBBOLETH

入口



OPENATHENS REGISTERED SITES

List of OpenAthens registered sites. If you don't see your institution, contact your library.

[VIEW ALL](#)

PUBLIC HEALTH ALERTS

Reports from the Frontlines

Receive immediate
email notification when
new reports are published.

NEJM
Evidence

[SIGN UP →](#)

④ 输入 SUN YAT-SEN UNIVERSITY 跳转CAS 登录中山大学NETID账号

The NEW ENGLAND JOURNAL of MEDICINE

CURRENT ISSUE ▾ SPECIALTIES ▾ TOPICS ▾

Sign In

INDIVIDUAL SIGN IN INSTITUTIONAL SIGN IN

LOG IN VIA SHIBBOLETH

← BACK TO INSTITUTIONAL SIGN IN

Type the name of your institution

☒ Use SeamlessAccess to remember this choice. [Learn more](#)

or

Find your Institution via Federation

https://cas.sysu.edu.cn/esc-ssu/login/page

简体中文

中山大学

即将访问: 默认身份认证

NetID登录

请输入 NetID

请输入密码

登录

激活NetID 找回NetID 忘记密码 需要帮助

全微信扫码登录

ADVERTISEMENT



Customized job opportunities direct to your inbox!

NEJM
CareerCenter

SIGN UP

广告

The New England Journal of Medicine

NEJM Clinician

NEJM Evidence

NEJM AI

NEJM Catalyst

NEJM Voices



SIGN IN

| CREATE ACCOUNT

SUBSCRIBE

Welcome: Sun Yat-Sen University



The NEW ENGLAND
JOURNAL of MEDICINE

⑤ 页面中间显示

CURRENT ISSUE

SPECIALTIES

TOPICS

MULTIMEDIA

LEARNING/CME

AUTHOR CENTER



Sun Yat-sen University

ORIGINAL ARTICLE CME

Milvexian after an Acute Coronary Syndrome Event

C.M. Gibson and Others

Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding.


Editorial Role for Factor XIa Inhibitors after an Acute
Coronary Syndrome Event

Quick Take Video RS Research Summary

即CARSI登录成功



IMAGE CHALLENGE



What is the diagnosis?

ANSWER →

Extend the